MOACM
KRYS icon

Mutual of America Capital Management’s Krystal Biotech KRYS Stock Holding History

Mutual of America Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Sell
31,998
-3,861
-11% -$1.15M 0.12% 164
2026
Q1 		$9.26M Sell
35,859
-1,410
-4% -$375K 0.11% 198
2025
Q4 		$9.19M Sell
37,269
-665
-2% -$140K 0.1% 205
2025
Q3 		$6.7M Sell
37,934
-423
-1% -$63.3K 0.07% 324
2025
Q2 		$5.27M Buy
38,357
+1,926
+5% +$283K 0.06% 416
2025
Q1 		$6.57M Sell
36,431
-87
-0.2% -$14.6K 0.08% 296
2024
Q4 		$5.72M Sell
36,518
-48
-0.1% -$8.52K 0.06% 377
2024
Q3 		$6.66M Sell
36,566
-758
-2% -$146K 0.07% 327
2024
Q2 		$6.85M Buy
37,324
+3,135
+9% +$526K 0.07% 295
2024
Q1 		$6.08M Sell
34,189
-2,199
-6% -$305K 0.07% 364
2023
Q4 		$4.51M Sell
36,388
-1,151
-3% -$128K 0.05% 510
2023
Q3 		$4.35M Sell
37,539
-962
-2% -$117K 0.05% 484
2023
Q2 		$4.52M Buy
38,501
+12,950
+51% +$1.32M 0.05% 516
2023
Q1 		$2.05M Sell
25,551
-1,177
-4% -$92.5K 0.02% 889
2022
Q4 		$2.12M Buy
26,728
+365
+1% +$27.1K 0.03% 882
2022
Q3 		$1.84M Sell
26,363
-2,401
-8% -$173K 0.02% 881
2022
Q2 		$1.89M Sell
28,764
-216
-0.7% -$13.4K 0.02% 899
2022
Q1 		$1.93M Sell
28,980
-1,257
-4% -$78.5K 0.02% 969
2021
Q4 		$2.12M Sell
30,237
-281
-0.9% -$16.4K 0.02% 960
2021
Q3 		$1.59M Sell
30,518
-438
-1% -$25.9K 0.02% 1008
2021
Q2 		$2.1M Sell
30,956
-1,333
-4% -$93K 0.02% 960
2021
Q1 		$2.49M Sell
32,289
-1,786
-5% -$130K 0.03% 870
2020
Q4 		$2.04M Buy
34,075
+5,006
+17% +$250K 0.02% 889
2020
Q3 		$1.25M Buy
29,069
+2,638
+10% +$115K 0.02% 997
2020
Q2 		$1.09M Sell
26,431
-1,788
-6% -$86K 0.02% 1027
2020
Q1 		$1.22M Sell
28,219
-1,241
-4% -$64.9K 0.02% 910
2019
Q4 		$1.63M Buy
+29,460
New +$1.45M 0.02% 994

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Mutual of America Capital Management's KRYS Position: Q2 2026 in Review

Mutual of America Capital Management reduced its Krystal Biotech (KRYS) stake by 11% in Q2 2026, selling an estimated $1.15M and leaving 31,998 shares worth $11.9M. The position accounts for 0.12% of the portfolio, ranked #164.

Mutual of America Capital Management first reported a position in KRYS in Q4 2019 and has held it in 27 quarters since. 264 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Mutual of America Capital Management held 31,998 shares of Krystal Biotech worth $11.9M as of Q2 2026.
  • Mutual of America Capital Management sold 3,861 Krystal Biotech shares in Q2 2026, an estimated $1.15M.
  • Krystal Biotech made up 0.12% of Mutual of America Capital Management's portfolio in Q2 2026, its #164 holding.
  • Mutual of America Capital Management first reported a position in Krystal Biotech in Q4 2019 and has held it in 27 quarters since.
  • 264 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Mutual of America Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.